Close Menu

NEW YORK – Agilent Technologies said today that it has agreed to acquire privately held life science instrumentation manufacturer BioTek Instruments for $1.17 billion in cash.

With anticipated tax benefits for Agilent, the net purchase price is expected to be approximately $1.05 billion. Agilent expects the transaction to be completed in its fiscal fourth quarter, subject to regulatory approvals.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.